Zhengye Biotechnology Holding (ZYBT) Assets Average (2024 - 2025)
Zhengye Biotechnology Holding (ZYBT) posted quarterly Assets Average of $66.0 million for Q4 2025, down 4.43% year-over-year from $69.0 million in Q4 2024, and down 5.12% quarter-over-quarter from $69.6 million in Q2 2025.
Zhengye Biotechnology Holding (ZYBT) Assets Average (2024 - 2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Assets Average for 2 consecutive years, with $66.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average fell 4.43% year-over-year to $66.0 million; the TTM figure through Dec 2025 stood at $66.0 million (down 4.43% YoY), while the FY2025 annual figure was $65.0 million, down 5.12% from the prior year.
- Assets Average slipped to $66.0 million in Q4 2025 per ZYBT's latest filing, from $69.6 million in the prior quarter.
- Across five years, Assets Average topped out at $69.6 million in Q2 2025 and bottomed at $66.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 5.97 Bn |
| 10 | Zhengye Biotechnology Holding | 88.07 Mn | 80.75 Mn | - | 65.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 65.99 Mn |
| Jun 30, 2025 | 69.56 Mn |
| Dec 31, 2024 | 69.05 Mn |